Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrastaurin plus tacrolimus versus mycophenolic acid plus tacrolimus in de novo kidney transplant recipients
NL-OMON34948Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sotrastaurin, tacrolimus and mycophenolic acid in kidney transplant (3 arms), sponsored by Novartis. Primary endpoint: Composite efficacy failure at Month 6. Started Sep 2010; status: active, not recruiting.
02
Drugs
sotrastaurintacrolimusmycophenolic acid
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON34948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34948.